@Article{,
AUTHOR = {Eric Berthelet, Tom Pickles, Pauline T. Truong, Mitchell Liu, Howard H. Pai, Winkle B. Kwan, Jan T.W. Lim},
TITLE = {What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {14},
YEAR = {2007},
NUMBER = {4},
PAGES = {3621--3627},
URL = {http://www.techscience.com/CJU/v14n4/62376},
ISSN = {1488-5581},
ABSTRACT = {<b>Purpose:</b> To evaluate the optimal duration of androgen deprivation therapy (ADT) in patients with prostate cancer treated with external beam radiotherapy (EBRT), who present with PSA levels >20 ng/mL.
<br/><b>Materials and methods:</b> A total of 307 patients presenting with a PSA >20 ng/ml were treated with EBRT and ADT. The cohort was divided into four groups according to the duration of ADT: Group 1 received <6 months (n=71), group 2 received 6-12 months (n=80), group 3 received 12-24 months (n=72), and group 4 received >24 months (n=84) of ADT. The endpoints analyzed were biochemical control (bNED), overall survival (OS) and cause-specific survival (CSS). Statistical analysis was conducted using Kaplan-Meier estimates and Cox regression models.
<br/><b>Results:</b> Compared to patients who received <6 months of ADT, patients treated with 12-24 months or >24 months of ADT experienced significantly improved bNED (p=0.01 and p<0.0001, respectively). Cause-specific survival with ADT durations 12-24 and >24 months were significantly higher compared to <6 months (p<0.007 and 0.024, respectively). Overall survival with ADT durations >24 months was also significantly higher compared to <6 months (p=0.0025).
<br/><b>Conclusions:</b> The present analysis supports the hypothesis that longer durations of ADT improves bNED, CSS and OS in patients presenting with a PSA >20 ng/ml.},
DOI = {}
}